Skip to content

MBX生物科技

US · MBX #2567 按市值排名 上市于 2024
49.61 -1.10 -2.17%
实时 - 追踪5344个代码 - 心跳于235秒前 · 2026-10-16 19:30

最新新闻

  • 公司公告
    4: MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Pescovitz Ora H.
    SEC · 2026/6/5
  • Truist Financial Maintains MBX Biosciences(MBX.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/7/16
  • 评级变动
    MBX Biosciences, Inc. (MBX) Gets a Buy From Mizuho Securities
    TipRanks · 2026/8/8
  • 公司公告
    MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Hawryluk P. Kent
    SEC · 2026/5/9
  • Guggenheim Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $150
    \u5e02\u573a\u8d44\u8baf · 2026/10/2
  • 评级变动
    Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $70
    \u5e02\u573a\u8d44\u8baf · 2026/8/13
  • 评级变动
    Analysts Offer Insights on NA Companies: BillionToOne, Inc. Class A (BLLN) and MBX Biosciences, Inc. (MBX)
    TipRanks · 2026/8/7
  • 公司公告
    4: MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Hoerter Steven L.
    SEC · 2026/8/4
  • 评级变动
    Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $88
    \u5e02\u573a\u8d44\u8baf · 2026/8/7
  • 评级变动
    LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $121
    \u5e02\u573a\u8d44\u8baf · 2026/8/7
  • 评级变动
    Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91
    \u5e02\u573a\u8d44\u8baf · 2026/8/8
  • 评级变动
    UBS Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $90
    \u5e02\u573a\u8d44\u8baf · 2026/7/24
  • J.P. Morgan Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88
    \u5e02\u573a\u8d44\u8baf · 2026/8/21
  • 公司公告
    MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L.
    SEC · 2026/5/4
  • 公司公告
    4: MBX Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Hoerter Steven L.
    SEC · 2026/6/5
  • MBX Biosciences Insiders Added US$1.06m Of Stock To Their Holdings
    Simply Wall St · 2026/8/25
  • 评级变动
    Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $91
    \u5e02\u573a\u8d44\u8baf · 2026/7/29
  • 评级变动
    LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $121
    \u5e02\u573a\u8d44\u8baf · 2026/8/8
  • 评级变动
    Analysts Offer Insights on NA Companies: MBX Biosciences, Inc. (MBX), Septerna, Inc. (SEPN) and Six Flags Entertainment Corporation (FUN)
    TipRanks · 2026/8/13
  • Truist Financial Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88
    \u5e02\u573a\u8d44\u8baf · 2026/8/10

新闻标题为自动聚合内容,未经我们团队独立核实或编辑。

报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

MBX生物科技 讨论区 0 条评论

发表评论